Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
- 1 November 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 6 (11), 871-880
- https://doi.org/10.1038/nrd2381
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood, 2006
- Multiplexed protein measurement: technologies and applications of protein and antibody arraysNature Reviews Drug Discovery, 2006
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences of the United States of America, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- Genomic and proteomic technologies for individualisation and improvement of cancer treatmentEuropean Journal Of Cancer, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylationBiochemical and Biophysical Research Communications, 2004
- Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis‐driven science in the post‐genomic eraBioEssays, 2003
- EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagationNature, 2003